 |
 |
[log in to unmask] wrote: > The Physicians' Desk Reference 55th edition 2001 www.pdr.net > is fresh from the press. One brief peek revealed : > > TASMAR > tolcapone > Tablets > Before prescribing TASMAR the phtsician should be thoroughly > familiar with the details of this prescribing information. > TASMAR should not be used by patients until there has > been a complete discussion if the risks and the patient has > provided written informed consent. Altogether a depressing situation. Roche must have thought they had a real winner, only to be bushwhacked by a rare circumstance that they couldn't foresee, which implied a risk that IMHO can never be proven one way or the other. On one hand we have a top PD scientist boldly stating that, with proper monitoring precautions, Tasmar is "perfectly safe" to use; but it seems that most European nations (Chris VdL, can you verify?} have still not approved it for use. Possibly because the initial recommended blood testing may fail to give adequate warning when it's most needed. And any trial to test that would be far too dangerous to the trial subjects. More's the pity, since Comtan, the only other COMT antagonist now available, isn't near so effective against PD. Cheers, Joe -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013